Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01380561 · ClinicalTrials.gov registry record · Phase 1

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

A Phase 1 study of Healthy, sponsored by Tioga Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT01380561 is a Phase 1 study of Healthy that has completed, run by Tioga Pharmaceuticals. The registered enrollment target is 6 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01380561, a Phase 1 study of Healthy, has completed, sponsored by Tioga Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers.

Conditions Studied

Interventions

  • DRUG asimadoline

Study Locations (1)

Kansas

  • Quintiles Phase 1 Unit - Overland Park

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2011-06
Est. Completion 2011-07
Phase Phase 1

Sponsor

Tioga Pharmaceuticals

6 total trials

What the Registry Record Tells You About NCT01380561

The ClinicalTrials.gov registry entry for NCT01380561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The listed sponsor is Tioga Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which asimadoline is the first listed.

NCT01380561 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT01380561 about?

NCT01380561 is a clinical study titled "A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers". This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers.

What is the current status of trial NCT01380561?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-06. Estimated completion is 2011-07.

What conditions does trial NCT01380561 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01380561?

The interventions under investigation include: asimadoline (DRUG).

Who is sponsoring clinical trial NCT01380561?

This trial is sponsored by Tioga Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01380561 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.